arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AYTU BIOPHARMA, INC

AYTU
$2.33 ▲ +0.03 (+1.30%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

AYTU BIOPHARMA, INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.6M
Dividend Yield
Revenue Growth -18.0%
Op. Margin -11.8%
ROIC -27.0%
FCF / Share $-0.34
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity 0.57
info Valuation on last close. End-of-day price, Aug 7, 2026.

21-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$66.38M
↓ -18.0%
Net Income Profit after all expenses
$-13.56M
↑ +14.4%
Operating Margin Operating profit as % of sales
-11.8%
↓ -81.8% 14th
FCF / Share Free cash flow per share
$-0.34
↓ -37.6%
Long-Term Debt Long-term obligations
$10.89M
— +0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
12
Financial Health
43
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 21 years · 85 quarters